Drugs / MB07811
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04173065 | Nov 2019 → May 2023 | metabolic dysfunction-associated steatohepatitis | Viking Therapeutics, Inc. | Completed | Met primary |
| Phase 2 | NCT02927184 | Sep 2016 → Mar 2019 | NAFLD1, hyperlipidemia | Viking Therapeutics, Inc. | Completed | Met primary |
| Phase 2 | NCT00879112 | Apr → Dec 2009 | hyperlipidemia | Ligand Pharmaceuticals | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 21
| Date | Issuer | Release |
|---|---|---|
| 2024-11-19 | Viking Therapeutics, Inc. | Results Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 vikingtherapeutics.com ↗
The presentation summarized the final 52-week data from the VOYAGE study, showing that VK2809 successfully achieved the trial's primary and secondary endpoints while demonstrating excellent tolerability and promising safety. |
| 2024-06-04 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) vikingtherapeutics.com ↗ |
| 2023-11-13 | Viking Therapeutics, Inc. | Results Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023 vikingtherapeutics.com ↗
Newly reported findings demonstrated robust and comparable liver fat reductions among patients with or without type 2 diabetes, as well as patients with either F2 or F3 fibrosis. |
| 2023-05-16 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) vikingtherapeutics.com ↗ |
| 2023-05-16 | Ligand Pharmaceuticals | Results Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) ligand.com ↗ |
| 2020-08-28 | Viking Therapeutics, Inc. | Results Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020 vikingtherapeutics.com ↗ |
| 2019-11-05 | Viking Therapeutics, Inc. | Regulatory Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update vikingtherapeutics.com ↗
This work, along with data from completed clinical and other non-clinical studies, formed the basis of an IND application that was submitted to the FDA to initiate a Phase 2b study of VK2809 in patients with biopsy-confirmed NASH. |
| 2019-04-11 | Viking Therapeutics, Inc. | Results Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019 vikingtherapeutics.com ↗
Patients in the VK2809 5 mg cohort also experienced a statistically significant median relative reduction in liver fat content of 53.8%. |
| 2019-04-04 | Viking Therapeutics, Inc. | Results Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019 vikingtherapeutics.com ↗
Consistent with prior data from the 10 mg cohorts, VK2809 was well tolerated when dosed at 5 mg daily, and no serious adverse events were reported among patients receiving either VK2809 or placebo. |
| 2018-11-12 | Viking Therapeutics, Inc. | Results Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver Meeting® 2018 vikingtherapeutics.com ↗
The study successfully achieved its primary endpoint, with patients receiving VK2809 demonstrating statistically significant reductions in LDL-C compared with placebo following 12 weeks of treatment. |
| 2018-10-08 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting of American Thyroid Association (ATA) vikingtherapeutics.com ↗
The results demonstrated that treatment with VK2809 led to an overall improvement in liver health highlighted by restoration of autophagy, reduction in steatosis, and improvements in inflammation and liver size. |
| 2018-09-18 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol vikingtherapeutics.com ↗
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from a 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C). |
| 2017-10-24 | Viking Therapeutics, Inc. | Results Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) vikingtherapeutics.com ↗
today announced positive final results from an eight-week study of VK2809 in an in vivo model of non-alcoholic steatohepatitis (NASH). |
| 2017-09-11 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) vikingtherapeutics.com ↗
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from a gene expression analysis conducted as part of its recently completed study of VK2809 in an in vivo model of diet-induced non-alcoholic steatohepatitis (NASH). |
| 2017-09-07 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) vikingtherapeutics.com ↗
The study results demonstrated that treatment with VK2809 produced statistically significant reductions in liver triglyceride content and liver weight compared with vehicle-treated controls. |
| 2017-08-09 | Viking Therapeutics, Inc. | Results Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update vikingtherapeutics.com ↗
In addition, we announced positive results from a study of VK2809 in a model of diet-induced NASH, which showed statistically significant reductions in fibrosis, liver collagen, liver steatosis, and the NAFLD activity score (NAS). |
| 2017-06-06 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) vikingtherapeutics.com ↗
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top line results from a study of VK2809 in an in vivo model of non-alcoholic steatohepatitis (NASH). |
| 2017-02-09 | Viking Therapeutics, Inc. | Results Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) vikingtherapeutics.com ↗
Data to date showed that treatment with VK2809 produced rapid and substantial reductions in liver triglyceride content, liver weight and liver weight as a percentage of body weight compared with vehicle-treated controls. |
| 2016-11-15 | Viking Therapeutics, Inc. | Results Viking Therapeutics Presents New Clinical Data on VK2809 in Subjects with Elevated Cholesterol at American Heart Association Scientific Sessions 2016 vikingtherapeutics.com ↗
Data from an analysis of the study participants' atherogenic protein levels demonstrated that subjects experienced statistically significant reductions in lipoprotein(a) [Lp(a)] and apolipoprotein B-100 (apo B). |
| 2016-04-11 | Viking Therapeutics, Inc. | Results Viking Therapeutics Presents Positive Phase 1b Clinical Data on VK2809 in Hypercholesterolemic Subjects vikingtherapeutics.com ↗
The results demonstrated substantial and clinically meaningful reductions in subjects' low-density lipoprotein cholesterol (LDL-C), triglycerides, and atherogenic proteins lipoprotein-a and apolipoprotein B following 14 days of treatment. |
| 2015-11-17 | Viking Therapeutics, Inc. | Regulatory Viking Therapeutics Submits Investigational New Drug (IND) Application to Conduct Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Fatty Liver Disease vikingtherapeutics.com ↗ |
All press releases naming this drug 30 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB07811 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00879112 ↗ |
| Known as | VK2809 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04173065 ↗ |
| Action | Activate | “Thyroid hormone receptor beta-1 agonist” CHEMBL471897 ↗ |
| Modality | Small molecule | — CHEMBL471897 ↗ |
| Route | Oral | “MB07811 given orally” NCT00879112 ↗ |
| Target | THRB | “Thyroid hormone receptor beta-1 agonist” CHEMBL471897 ↗ |